But the FDA’s investigation looks like worse news for autoimmune disease than oncology.

Failure of a subcutaneous formulation of Vyvgart raises questions about the drug’s future in primary immune thrombocytopenia and beyond.

The latest first-in-human entrants include an anti-TROP2 ADC from Jiangsu Hansoh and a mystery bispecific from Johnson & Johnson.

Against the odds GSK’s Dreamm-7 study yields a positive survival readout.

But, with the end in sight for the CD38 blockbuster, will Johnson & Johnson buy into Genmab’s next-gen project?

Pelabresib’s Manifest-2 trial yields mixed data, but the bad part could render the whole unpalatable.